Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Update

Avenue Therapeutics, Inc. (NASDAQ:ATXI) saw a significant decline in short interest in the month of February. As of February 28th, there was short interest totalling 59,700 shares, a decline of 35.2% from the February 13th total of 92,200 shares. Based on an average trading volume of 376,300 shares, the short-interest ratio is presently 0.2 days. Approximately 3.4% of the shares of the company are sold short.

Avenue Therapeutics Stock Performance

ATXI stock opened at $0.85 on Monday. The company has a market cap of $1.74 million, a price-to-earnings ratio of 0.05 and a beta of -0.29. The business’s 50-day moving average is $1.41 and its two-hundred day moving average is $1.91. Avenue Therapeutics has a fifty-two week low of $0.72 and a fifty-two week high of $12.75.

Institutional Investors Weigh In On Avenue Therapeutics

A hedge fund recently bought a new stake in Avenue Therapeutics stock. Boothbay Fund Management LLC bought a new stake in shares of Avenue Therapeutics, Inc. (NASDAQ:ATXI) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 41,089 shares of the company’s stock, valued at approximately $82,000. Boothbay Fund Management LLC owned about 2.00% of Avenue Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 17.34% of the company’s stock.

About Avenue Therapeutics

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.